- Home
- LGCL vs BDSX Comparison
LGCL vs BDSX Comparison
Compare LGCL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- BDSX
- Stock Information
- Founded
- LGCL 2009
- BDSX 2005
- Country
- LGCL China
- BDSX United States
- Employees
- LGCL N/A
- BDSX N/A
- Industry
- LGCL
- BDSX Precision Instruments
- Sector
- LGCL
- BDSX Health Care
- Exchange
- LGCL NYSE
- BDSX Nasdaq
- Market Cap
- LGCL 119.4M
- BDSX 115.4M
- IPO Year
- LGCL 2024
- BDSX 2020
- Fundamental
- Price
- LGCL $0.83
- BDSX $0.45
- Analyst Decision
- LGCL
- BDSX Strong Buy
- Analyst Count
- LGCL 0
- BDSX 5
- Target Price
- LGCL N/A
- BDSX $1.75
- AVG Volume (30 Days)
- LGCL 179.0K
- BDSX 1.1M
- Earning Date
- LGCL 01-01-0001
- BDSX 08-07-2025
- Dividend Yield
- LGCL N/A
- BDSX N/A
- EPS Growth
- LGCL N/A
- BDSX N/A
- EPS
- LGCL 0.07
- BDSX N/A
- Revenue
- LGCL $145,690,427.00
- BDSX $74,463,000.00
- Revenue This Year
- LGCL N/A
- BDSX $17.29
- Revenue Next Year
- LGCL N/A
- BDSX $29.33
- P/E Ratio
- LGCL $12.12
- BDSX N/A
- Revenue Growth
- LGCL N/A
- BDSX 35.76
- 52 Week Low
- LGCL $0.28
- BDSX $0.17
- 52 Week High
- LGCL $3.31
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- BDSX 75.72
- Support Level
- LGCL N/A
- BDSX $0.29
- Resistance Level
- LGCL N/A
- BDSX $0.44
- Average True Range (ATR)
- LGCL 0.00
- BDSX 0.03
- MACD
- LGCL 0.00
- BDSX 0.02
- Stochastic Oscillator
- LGCL 0.00
- BDSX 98.04
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.